Biotech entity
Every one of those 1 sits in a single category, fda-approval. Of the tracked stories, 1 of 1 also mention Dr. Brandon Jones, the most common co-covered peer. The tracked stories average 2 original sources each. Laplace Interventional appears in 1 tracked Biotech story from July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. Of the tracked stories, 1 of 1 also mention Dr. Brandon Jones, the most common co-covered peer. The tracked stories average 2 original sources each. Laplace Interventional appears in 1 tracked Biotech story from July 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Laplace Interventional. Shared-story counts are live from our verified record — not editorial picks.
Laplace Interventional has obtained FDA IDE approval for its TRIUMPH pivotal trial, targeting 400 patients across 75 sites to test its transcatheter tricuspid valve replacement device. The study includes a 2:1 randomization against commercial TTVR and a 150-patient registry for harder-to-treat patients. Top U.S. cardiologists will lead the trial, building on promising early feasibility data.
Source: prnewswire.com · newswise.com
Laplace Interventional is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
